Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia

Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia

The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country, in the following sub-populations:

• Primary/secondary prevention patients.
• Patients with metabolic syndrome (according to NCEP III definition).

In addition, the purpose is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in the following sub-populations:

• Primary/secondary prevention patients.
• Patients with metabolic syndrome.

Inclusion Criteria:

• On lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks. ·
• Subject must sign informed consent

Exclusion Criteria:

• Subjects who are unwilling or unable to provide informed consent.